Last reviewed 2026-04-23 · How we verify

C-KAD Ophthalmic Solution

C-KAD Ophthalmic Solution is an investigational ocular therapeutic in phase 2 development by Chakshu Research, Inc., with mechanism details not publicly disclosed.

C-KAD Ophthalmic Solution is an investigational ocular therapeutic in phase 2 development by Chakshu Research, Inc., with mechanism details not publicly disclosed. Used for Indication(s) under investigation in phase 2 (specific indication not publicly available).

At a glance

Mechanism of action

Limited public information is available on C-KAD's specific molecular mechanism. As an ophthalmic solution in early-stage development, it is likely designed to treat an eye condition through topical ocular delivery, but the exact target, drug class, and mechanism of action require access to proprietary clinical trial data or company disclosures.

Approved indications

• Indication(s) under investigation in phase 2 (specific indication not publicly available)

Common side effects

No common side effects on file.

Key clinical trials

• The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract (PHASE1, PHASE2)
• An Open-Label Study of an Ophthalmic Solution to Reduce Intraocular Pressure in Patients With Ocular Hypertension (NA)
• An Open-Label Study of the Effect of an Ophthalmic Solution on Asteroid Hyalosis (PHASE2)
• Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract (PHASE2)
• Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related Cataract (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.